Graphite Bio Inc   (GRPH)
Other Ticker:  
Price: $3.0300 $0.03 1.000%
Day's High: $3.205 Week Perf: 2.71 %
Day's Low: $ 2.95 30 Day Perf: 1.34 %
Volume (M): 282 52 Wk High: $ 3.43
Volume (M$): $ 854 52 Wk Avg: $2.60
Open: $3.00 52 Wk Low: $2.01

 Market Capitalization (Millions $) 173
 Shares Outstanding (Millions) 57
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -126
 Cash Flow (TTM) (Millions $) 127
 Capital Exp. (TTM) (Millions $) 12

Graphite Bio Inc
Graphite Bio Inc is a biotechnology company focused on developing genetic medicines to treat rare diseases. Their approach involves using gene editing technology and next-generation AAV gene therapy platforms to develop precise and efficient treatments. Graphite Bio aims to address the limitations of traditional gene therapies by utilizing advanced technologies to optimize therapeutic outcomes. Their goal is to bring transformative treatments to patients with rare diseases that currently have limited or no treatment options.

   Company Address: 611 Gateway Blvd South San Francisco 94080 CA
   Company Phone Number: 484-0886   Stock Exchange / Ticker: NASDAQ GRPH
   GRPH is expected to report next financial results on March 19, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Graphite Bio Inc

Biotechnology & Pharmaceuticals Company Graphite Bio Inc. Records Significant Operating Loss of $-25.027 Million in Fiscal Year Ending September 30, 2023

Graphite Bio Inc Surprises Investors with Improved Operating Losses
In the midst of the July to September 30, 2023 reporting season, Graphite Bio Inc (GRPH) has caught many investors off guard with unexpected adjustments to its revenue. Shareholders, however, are finding solace in the company's improved operating losses, giving hope for the future.
During the same period, Graphite Bio Inc recorded an operating loss of $-25.027 million, which is perceived as a positive surprise considering it outperformed the operating loss of $-26.154 million from the previous year. This enhancement in operating losses has bolstered confidence among numerous market participants.

Graphite Bio Inc

Graphite Bio Inc Faces Mounting Financial Challenges as Operating Losses Soar in Q2 2023

As the Biotechnology & Pharmaceuticals sector continues to attract attention from Wall Street investors, some lesser-known businesses are emerging with their financial results. Graphite Bio Inc (GRPH), in particular, has reported an alarming operating loss of $-58.159 million in the second quarter of 2023. This figure marks a significant increase from the operating loss of $-26.776 million recorded in the same quarter the previous year. With a net deficit of $-55.314 million, Graphite Bio Inc is facing an uphill battle to improve its financial performance.
Analysing the Financial Results
When examining the financial results of Graphite Bio Inc, it is evident that the company is struggling to achieve profitability. The absence of top-line growth and the substantial net deficit indicate a concerning trend. Moreover, the net deficit has undergone significant growth, nearly doubling from $-25.936 million in the same period last year.

Graphite Bio Inc

Graphite Bio Inc. Reports a Deterioration in Operating Performance for Q1 2023

Specialty Retail Sector Experts Analyze Graphite Bio Inc's First Quarter Performance
As the first quarter of 2023 comes to an end, specialty retail sector experts continue to analyze the financial performance of various companies in the market. The latest attention has been focused on the Graphite Bio Inc., which has recorded an operating loss of $-26.45 million. Disappointingly, the company has not cited any revenue yet for its January to March 31, 2023, reporting period.
Experts in the industry have noted that the operating loss has worsened compared to the first quarter of 2022, where Graphite Bio Inc. recorded an operating loss of $-25.958 million. However, what is causing more concern is the speculation about when the company could start to generate revenue.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com